Skip to main content
Immuneering Corp logo

Immuneering Corp — Investor Relations & Filings

Ticker · IMRX ISIN · US45254E1073 US Professional, scientific and technical activities
Filings indexed 300 across all filing types
Latest filing 2023-05-04 Interim / Quarterly Rep…
Country US United States of America
Listing US IMRX

About Immuneering Corp

https://immuneering.com/

Immuneering Corp. is a clinical-stage oncology company focused on developing medicines for broad populations of cancer patients. The company utilizes its proprietary computational Disease Cancelling Technology to design and develop novel therapeutics. Its lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily deep cyclic inhibitor of the MEK pathway. Atebimetinib is being evaluated in Phase 2a clinical trials for patients with advanced solid tumors, including pancreatic cancer. The drug is designed to maximize therapeutic activity while providing an improved tolerability profile, with the goal of helping patients outlive their disease.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2023
2023-05-04 English
8-K
Regulatory Filings
2023-05-04 English
DEFA14A
Regulatory Filings
2023-05-01 English
DEF 14A
Proxy Solicitation & Information Statement
2023-05-01 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-04-24 English
Director's Dealing 2023
Director's Dealing
2023-04-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.